1227911-45-6 (3S,6R)-1-(6-(3-氨基-1H-吲唑-6-基)-2-(甲基氨基)嘧啶-4-基)-N-环己基-6-甲基哌啶-3-甲酰胺

危险性质：非危险化学品

• 体外研究 在含PtdIns(3,4,5)P 3 465E/K465E 2+ 2+
• 靶点 IC50: 10 nM(PDK1)
• 体内研究 Braf V600E ::Pten −/− mice subjected to systemic administration of 4-HT. Twice weekly administration of PDK1 results in marked inhibition of pigmented lesions and concomitant melanomagenesis, as well as significant inhibition of lung metastases, seen by H&E staining-based quantification (~80%), and lymph node metastases as by S100 immunostaining, similar to the phenotype seen upon genetic ablation of Pdk1 .

医药